When I first came to The Children’s Inn in June of 2016, I had no idea what it would mean to me. The next several months, though, certainly ended up being some of the most transformational months of my life. I first came to The Inn as a 19-year-old who had somehow managed to finish his first year of college, even while dealing with a harsh genetic disease known as sickle cell anemia. After staying at The Inn for nearly five months, I left as a man, entering his second year of college, having been healed from the disease that once shaped his life.
My 8-year-old nephew Luke has a sixth-grade reading level, while still in the third grade. Yet, he often struggles to finish his chores. He carries a timer in his backpack to keep himself on task. His school provides Luke with special assistance, including extra time for tests and repeated, detailed instruction. The challenges arise because Luke, like his mother Rebecca, has attention-deficit/hyperactivity disorder (ADHD).
Isaac was born to fight. Arriving more than five weeks early by emergency C-section, it wasn’t just his way of coming into the world that made him different from his three brothers. While he initially looked healthy, his parents soon realized Isaac’s health was something he and the entire family would need to be fighting for every single day.
Last month I moderated our annual retreat with the NIH Scientific Directors, those individuals tasked with leading their Institute or Center (IC)-based intramural research program. We were joined by many of the IC Clinical Directors. And this year we decided to do something a little different: listen to a series of talks about exciting, new IRP research.
The surprising results of an animal study are raising hopes for a far simpler treatment regimen for people infected with the AIDS-causing human immunodeficiency virus (HIV). Currently, HIV-infected individuals can live a near normal life span if, every day, they take a complex combination of drugs called antiretroviral therapy (ART). The bad news is if they stop ART, the small amounts of HIV that still lurk in their bodies can bounce back and infect key immune cells, called CD4 T cells, resulting in life-threatening suppression of their immune systems.
If you were going to train an artificial intelligence (AI) system to understand and accurately diagnose medical images, what kind of information do you think would be most effective: lots of general image data, or small amounts of specific data?
“I kind of made it a mission of mine to find out as much as I can, what’s available out there as treatments, trials,” John says, “and just my way of giving back, whether it helps me directly or somebody who comes after me.”
Hi, my name is James. I’ve always really liked science and I want to be a scientist when I grow up, but I never got to see where scientists work until I went to Take Your Child to Work Day at NIH with my Auntie Kit. It was awesome!
Last month we lost a remarkable investigator, Robert Nussenblatt, M.D., M.P.H., chief of the Laboratory of Immunology at the National Eye Institute (NEI). Bob was a world-renowned expert in uveitis, an inflammatory eye disease and a leading cause of blindness in younger people. He was instrumental in establishing the pathology of and treatment for uveitis. Bob was diagnosed with a metastatic cancer just a few months ago. He remained characteristically optimistic even as his prognosis rapidly grew worse. He died on April 17, 2016, at age 67 with his family by his side. The NIH staff just devastated to hear the news of his death, because so few knew Bob was ill.
Have you ever had a PET scan? (That’s short for positron emission tomography.) This computer board, called a discriminator, was one of 64 in the Neuro-PET scanner designed and built at the NIH under the direction of Dr. Giovanni De Chiro.